The m6A modification is widely present in cancer cells, but the various levels of m6A in different cancers also predict the diversity of regulatory mechanisms.[41, 42, 43] Hypomethylation in conjunctival melanoma has been shown to promote melanoma development due to reduced recognition of m6A by YTHDF2, which inhibits mRNA degradation and promotes the translation process.[31] However, our studies on cutaneous melanoma have demonstrated that the knockdown of DHPS reduces both YTHDF2 and METTL3 proteins. The gene discussed is METTL3; the disease is melanoma.